Navigation Links
Celleration Appoints Mark T. Wagner President and Chief Executive Officer
Date:7/1/2009

EDEN PRAIRIE, Minn., July 1 /PRNewswire/ -- Celleration, Inc., developer of the patented MIST Therapy(R) System, an innovative device that uses ultrasound to heal wounds, has named Mark T. Wagner as president and chief executive officer and member of Celleration's board of directors. Mr. Wagner brings a successful track record of developing and commercializing medical devices spanning 30 years to the Celleration team.

"We are delighted by the addition of Mark to the Celleration team," said Ed Spencer, Jr., Chairman of Affinity Capital Management and Chairman of Celleration's board of directors. "Mark brings a wealth of experience and a solid history of building companies and delivering results. We are absolutely confident in Mark's ability to take Celleration to its next stage of commercialization and build value for its shareholders."

Mr. Wagner has decades of leadership experience in the medical device field. Most recently, he co-founded and is Board Chairman of Orasi Medical, a spinout from the University of Minnesota that is developing a diagnostic tool for neurological diseases. Prior to co-founding Orasi, Wagner served as CEO at multiple companies including, ProVation Medical, Survivalink and Altiva. Over the course of his career, Mr. Wagner has held positions of Vice President and General Manager of Nellcor's Global Sleep Solutions Group and executive positions with GE Medical Systems. Mr. Wagner currently serves on the board of directors of BioMedix Inc. and Vital Medix. Mr. Wagner holds a BS in Business Administration from the University of Southern California.

Kevin Nickels, the previous CEO, will continue to serve as the Chief Technology and Business Development Officer. Mr. Spencer commented, "During his seven years as CEO, Kevin made a huge contribution to the development of the business and I am delighted that we will continue to have the benefit of his vision in his new role as Chief Technology and Business Development Officer."

About Celleration, Inc.:

Celleration, Inc., a privately held medical device company, was founded in 1999 to develop and commercialize its therapeutic ultrasound platform. The patented MIST Technology delivers non-contact, low-frequency, low-intensity ultrasound to the patient's injured soft tissue in a painless fashion. The chronic diabetic foot ulcer market had been the Company's initial focus. MIST Therapy(R) has since expanded to various hard to heal, chronic wounds benefiting from higher incidence of complete healing in less time than standard of care. The end results, improving patient outcomes at a lower cost to the health care industry. In addition to the Company's prospective, randomized, double-blind, sham-controlled multi-center study in diabetic foot ulcers, which resulted in a statistically significant improvement in the rate of wound closure and time to wound closure, numerous independent clinical researchers without funding from the Company has further validated this value proposition.

    Contacts:
    Chris Geyen, Chief Financial Officer
    952-224-8700

    Richard Lewis Communications, Inc.
    212-827-0020
    Andrew Mielach, Media
    amielach@rlcinc.com
    Cecelia Heer, Investors
    cheer@rlcinc.com


'/>"/>
SOURCE Celleration, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. XLHealth Appoints New Vice President of Contracting and Provider Relations
2. Wisconsin Tobacco Tax Increase Is Positive Step for Health, but Budget Disappoints by Cutting Funding for Tobacco Prevention Programs
3. Verathon Inc. Appoints Kendall Stever as Chief Financial Officer
4. Tyco Electronics Appoints Cuong Do as Senior Vice President, Corporate Strategy & Business Development
5. Symmetry Medical Appoints Chairman and Two Directors
6. GBS/CIDP Foundation International Appoints Patricia A. Bryant as Executive Director
7. DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
8. Cinergy Health Appoints Dr. Erika Schwartz as Medical Director
9. ThermoGenesis Appoints Chief Executive Officer J. Melville (Mel) Engle to Board of Directors
10. China Nepstar Chain Drugstore Appoints Chief Operating Officer
11. Darwin Appoints Becky Cox Vice President, Business Development, Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... FL (PRWEB) , ... February 13, 2016 , ... The ... environmental impact of American businesses. , The increasingly modern world of instantaneous consumption ... often on non-renewable energy sources such as oil and coal, which pollutes our air, ...
(Date:2/13/2016)... ... 2016 , ... When an Au Pair comes all the way around the world ... for and they are often worried things won’t go well. More often than not, however, ... Au Pair of the Year winner’s all commented how their Au Pairs have become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article published February ... a significant portion of hernia repairs throughout the United States. Commenting on this article, ... notes that this trend has not only been expected, but it seems to be ...
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
(Date:2/12/2016)... VA (PRWEB) , ... February 12, 2016 , ... ... Feb. 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... in the life cycle of pharmaceutical products, garnering increased attention from all stakeholders ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016  This month,s issue of the ... takes an in-depth look at various causes and ... prescription drug spending, which has generated significant public outrage ... Editor-in-Chief Laura E. Happe , PharmD, MPH. ... , PharmD, MPH. --> In 2014 prescription ...
(Date:2/12/2016)... MONTREAL , February 12, 2016 ... sofern nicht anders vermerkt)   ... Unternehmens http://www.telestatherapeutics.com abrufbar.    ... Website des Unternehmens http://www.telestatherapeutics.com ... Inc. (TSX:TST; PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss ...
(Date:2/12/2016)... Feb. 12, 2016  Sequent Medical, Inc. announced today ... to evaluate the safety and effectiveness of the WEB™ ... ruptured intracranial aneurysms.  Prof Laurent Spelle , MD, ... Paris, France and Principal Investigator of ... France and Germany.  Although patients with ...
Breaking Medicine Technology: